Latham Named Life Sciences Practice Group of the Year
Latham has been recognized as Life Sciences Group of the Year by Law360 for litigation wins and significant transaction work that resonated throughout the legal industry in 2024. Our global reach continues to set the firm’s life sciences practice from its competitors, leveraging deep sector knowledge ranging from transactions, litigation, capital markets, and licensing to taxation, investigations, regulatory advice, and intellectual property.
Among the high-profile matters that firmly placed Latham at the head of the pack is our representation of GRAIL in which Latham scored a significant victory before the European Court of Justice in a landmark case and advocating for a fair and just interpretation of the regulatory framework; our work with Edwards Lifesciences to secure dismissal of a US$300 million complaint in Delaware’s Court of Chancery and perfected the victory when the state’s Supreme Court affirmed in July 2024; representing United Therapeutics in a pivotal case involving the federal 340B drug pricing program, which requires drug manufacturers to provide significant discounts to certain healthcare providers; advising CG Oncology on its upsized IPO, marking the first biotech IPO of 2024 and leading the way for a resurgence for life sciences companies pursing public offerings; and advising Cerevel Therapeutics in its “monumental” US$8.7 billion acquisition by AbbVie. The winning nomination also highlighted our deep regulatory prowess, as exemplified in our representation of Onkos Surgical, an orthopedic implant manufacturer, in connection with its De Novo classification request for the ELEOSx Limb Salvage System, an innovative polymer designed to combat infections for oncology patients receiving orthopedic implants.
“We set out decades ago to be able to work with life sciences companies in really every key area that they face — whether that be corporate capital markets, mergers and acquisitions, licensing, regulatory, antitrust, IP litigation, compliance and enforcement — and be able to grow with them domestically and internationally,” John Manthei, Global Chair of Latham’s Healthcare & Life Sciences Practice, said in the profile. “We wanted to be able to offer market-leading practices in each of those core areas, so clients could come to us and work in one firm in a really coordinated way. I think it's a real reason why clients have stuck with us.”
Along with Life Sciences, Law360 recognized Latham as Practice Group of the Year for Capital Markets, Cybersecurity & Privacy, Fintech, M&A, and Private Equity.